These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 3285909)
41. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Badar T; Patel KP; Thompson PA; DiNardo C; Takahashi K; Cabrero M; Borthakur G; Cortes J; Konopleva M; Kadia T; Bohannan Z; Pierce S; Jabbour EJ; Ravandi F; Daver N; Luthra R; Kantarjian H; Garcia-Manero G Leuk Res; 2015 Dec; 39(12):1367-74. PubMed ID: 26547258 [TBL] [Abstract][Full Text] [Related]
42. Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. Ravoet C; Mineur P; Robin V; Debusscher L; Bosly A; André M; El Housni H; Soree A; Bron D; Martiat P Ann Hematol; 2008 Nov; 87(11):881-5. PubMed ID: 18641985 [TBL] [Abstract][Full Text] [Related]
43. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908 [TBL] [Abstract][Full Text] [Related]
44. Mutations of the RAS genes in childhood acute myeloid leukemia, myelodysplastic syndrome and juvenile chronic myelocytic leukemia. Sheng XM; Kawamura M; Ohnishi H; Ida K; Hanada R; Kojima S; Kobayashi M; Bessho F; Yanagisawa M; Hayashi Y Leuk Res; 1997 Aug; 21(8):697-701. PubMed ID: 9379676 [TBL] [Abstract][Full Text] [Related]
45. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Hirsch-Ginsberg C; LeMaistre AC; Kantarjian H; Talpaz M; Cork A; Freireich EJ; Trujillo JM; Lee MS; Stass SA Blood; 1990 Sep; 76(6):1214-9. PubMed ID: 2205309 [TBL] [Abstract][Full Text] [Related]
46. Analysis of immunohistochemical results of the ras oncogene product p21 in myelodysplastic syndromes. Kalmantis T; Kalmanti M; Vassilaki M; Spandidos DA Anticancer Res; 1993; 13(4):1103-6. PubMed ID: 8352532 [TBL] [Abstract][Full Text] [Related]
47. p53 mutation in the myelodysplastic syndromes. Adamson DJ; Dawson AA; Bennett B; King DJ; Haites NE Br J Haematol; 1995 Jan; 89(1):61-6. PubMed ID: 7833278 [TBL] [Abstract][Full Text] [Related]
48. Transforming genes and chromosome aberrations in therapy-related leukemia and myelodysplastic syndrome. Inokuchi K; Amuro N; Futaki M; Dan K; Shinohara T; Kuriya S; Okazaki T; Nomura T Ann Hematol; 1991 Jun; 62(6):211-6. PubMed ID: 1854883 [TBL] [Abstract][Full Text] [Related]
49. Longitudinal analysis of point mutations of the N-ras proto-oncogene in patients with myelodysplasia using archived blood smears. van Kamp H; de Pijper C; Verlaan-de Vries M; Bos JL; Leeksma CH; Kerkhofs H; Willemze R; Fibbe WE; Landegent JE Blood; 1992 Mar; 79(5):1266-70. PubMed ID: 1536950 [TBL] [Abstract][Full Text] [Related]
58. Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers. Xu L; Gu ZH; Li Y; Zhang JL; Chang CK; Pan CM; Shi JY; Shen Y; Chen B; Wang YY; Jiang L; Lu J; Xu X; Tan JL; Chen Y; Wang SY; Li X; Chen Z; Chen SJ Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8589-94. PubMed ID: 24850867 [TBL] [Abstract][Full Text] [Related]
59. Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia. Tobal K; Pagliuca A; Bhatt B; Bailey N; Layton DM; Mufti GJ Leukemia; 1990 Jul; 4(7):486-9. PubMed ID: 2142747 [TBL] [Abstract][Full Text] [Related]
60. [Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome]. Yao DM; Qian J; Xu WR; Lin J; Jiang YW; Fei X; Han LX; Wang Y; Cen JN; Chen ZX Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):36-9. PubMed ID: 18247301 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]